Please login to the form below

Not currently logged in

Alliance Pharma's profit up 17 per cent

Alliance Pharma has recorded a net profit increase of 17 per cent for the first half of 2011, with sales up 4 per cent

Alliance Pharma has recorded a net profit increase of 17 per cent for the first half of 2011.

The speciality pharmaceutical company made a pre-tax profit of £7m for the period compared to £6m for the first half of 2010.

Sales were also up, increasing by 4 per cent from £23.4m for the first half of 2010 to £24.4m for the same period of 2011.

The company also announced the acquisition of UK marketing rights to six products from Beacon Pharmaceuticals for £2.4m. The products include acne treatment Rizuderm (isotretinoin).

The move follows previous acquisitions for Alliance this year, including the pain relief therapy Anbesol (benzocaine).

Michael Gatenby, chairman of Alliance Pharma, said: "We are delighted with the two earnings-enhancing acquisitions announced so far this year and continue to assess further opportunities."

7th September 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...